Precision AQ, a leader in life sciences commercialization and a driving force in expanding patient access to life-changing therapies, today announced the appointment of Dan Cummings as the company’s first Chief Commercial Officer. In this role, Dan Cummings will be responsible for Precision AQ’s commercial and go-to-market strategies, with the goal of bringing Precision AQ’s comprehensive suite of capabilities to help biopharmaceutical companies advance life-changing therapies to market.
The Precision AQ brand includes global capabilities across data and technology solutions, pricing and market access strategy, health economics and outcomes research, medical communications, market access, advertising and branding, omnichannel solutions, investor relations, and external communications.
Chad Clark, President and Chief Operating Officer of Precision Medicine Group
“We are delighted to welcome Dan as Precision AQ’s first Chief Commercial Officer. Dan brings a unique combination of skills that are highly relevant to our business, including an incredible track record of leading business development and sales operations for start-up and established life sciences companies, as well as experience in market access consulting. He is well-positioned to shape our commercial strategy as we continue synchronizing our evidence and access solutions and pursue our foundational mission of ensuring biopharmaceutical companies succeed in delivering transformative medicines to patients.”
Dan Cummings brings over a decade of strategy, planning, business development, growth marketing, and sales operations leadership experience to Precision AQ. Most recently, Mr. Cummings served as Senior Vice President, Head of Commercial Strategy and Operations at Envision Pharma Group, where he focused on driving growth and oversaw efforts across business development, go-to-market strategy, inside sales, and sales operations. Previously, he was Head of Commercial Operations and Sales at Capsule Pharmacy and, earlier, he held go-to-market-related roles of increasing global responsibility at Syneos Health. He started his career as a market access consultant at The Dedham Group and Decision Resources Group.
“In today’s environment, it is imperative that life science innovators approach drug development with an eye toward commercial viability, considering future questions around evidence and access in the earliest stages of new product planning,” said Mr. Cummings. “This creates an opportune moment for organizations like Precision AQ, which provide support across the product lifecycle and are purpose-built to address all access-related challenges companies face in commercializing new medicines. I am thrilled to join Precision AQ and am eager to bring a customer-first mindset to fully leverage Precision AQ’s connected offerings. As we continue to build on our legacy of successfully supporting the commercialization and launch of hundreds of transformative medicines, I am committed to ensuring that Precision AQ is easy to work with and easy to work for.”